{'fraction_non_alphanumeric': 0.04148660328435609, 'fraction_numerical': 0.028522039757994815, 'mean_word_length': 5.2594594594594595, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The clinicopathological roles of alpha‐B‐crystallin and p53 expression in patients with head and neck squamous cell carcinoma

Aims: The aim of the study was to investigate the expression of alpha‐B‐crystallin and p53 in head and neck squamous cell carcinoma (HNSCC). Methods: Alpha‐B‐crystallin and p53 expressions from 118 HNSCC were studied by immunohistochemistry and correlated with clinicopathological parameters. Results: Alpha‐B‐crystallin expression was seen in 28% (n = 33) of HNSCC. All except one poorly differentiated HNSCC were negative for alpha‐B‐crystallin. p53 expression was seen in 63% (n = 73) of HNSCC and was more common in moderately/poorly differentiated HNSCC (p = 0.034). The proportion of cases with positive staining for either alpha‐B‐crystallin or p53 was different in different anatomical locations in the head and neck. Patients with HNSCC having a high portion of tumour cells expressing p53 had a shorter survival than the other groups (p = 0.032). Conclusion: The expression of p53 and alpha‐B‐crystallin were related to the differentiation and site of the HNSCC. Alpha‐B‐crystallin was not a prognostic marker for HNSCC.